Expression analyses following MLL-AF9 withdrawal had prompted the authors to propose a model whereby MLL-AF9 enforces a Myb-coordinated program of aberrant self-renewal that involves genes linked to leukemia stem cell potential and poor prognosis in human AML patients. The gene discussed is MLLT3; the disease is leukemia.